PCSA (Processa Pharmaceuticals) Cash-to-Debt : 16.32 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Processa Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2024 was 16.32.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Processa Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Processa Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

PCSA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 7.57 Max: No Debt
Current: 29.8

During the past 13 years, Processa Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 7.57.

PCSA's Cash-to-Debt is ranked better than
65.99% of 1488 companies
in the Biotechnology industry
Industry Median: 7.4 vs PCSA: 29.80

Processa Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Processa Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Processa Pharmaceuticals Cash-to-Debt Chart

Processa Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

47.00

211.51

28.28

31.17

16.32

Processa Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															31.17	63.26	46.82	29.80	16.32

Competitive Comparison of Processa Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Processa Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Cash-to-Debt falls into.

Processa Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Processa Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.191	/	(0.073	+	0)
	=	16.32

Processa Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.191	/	(0.073	+	0)
	=	16.32

Processa Pharmaceuticals (NAS:PCSA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Processa Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Processa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076

Website

https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Executives

George K Ng	officer: Chief Executive Officer	C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke	director	C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
David Young	director, 10 percent owner, officer: President & CEO	8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin	officer: Chief Business - Strategy Off	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Wendy Guy	officer: Chief Administrative Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker	officer: Chief Financial Officer	9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson	director	319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu	director	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd	officer: Chief Operating Officer	C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora	officer: Chief Development Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076